Finotonlimab

DRUG3 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd., Sun Yat-sen University, Tang-Du Hospital

Conditions

Advanced Hepatocellular CarcinomaHead & Neck CancerHead and Neck CancerRecurrent Head and Neck Squamous Cell Carcinoma

Phase 2

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

RecruitingNCT06986785

Sichuan Baili Pharmaceutical Co., Ltd.Advanced Hepatocellular Carcinoma

Start: 2025-06-24End: 2027-12-01Target: 74Updated: 2026-06-10

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

Enrolling by invitationNCT07618624

Sun Yat-sen UniversityRecurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer

Start: 2026-04-20End: 2029-12-31Target: 42Updated: 2026-06-01

Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma

Not yet recruitingNCT07752394

Tang-Du HospitalHead & Neck Cancer

Start: 2026-08-23End: 2031-08-23Target: 15Updated: 2026-08-07